source
- Dren Bio secures $350 million to advance blood-cancer therapy toward 2027 launchDren Bio, a California biotech firm, announced it has closed a financing round that raised $350 million. The funding will be directed toward developing its lead blood‑cancer drug, with the company…
- Treasury's Proposed China Investment Rule Sparks Debate Over Licensing ExemptionsThe U.S. Treasury Department recently proposed a rule that would limit American investment in Chinese biotechnology companies, prompting immediate discussion among industry stakeholders. Commentat…